SciBase continues to demonstrate strong momentum across both commercial growth and strategic milestones, reinforcing its position as a leader in non-invasive skin diagnostics. Overall sales increased by 45% (+57% excluding currency effects), driven by solid performance in key markets. In Germany, the skin cancer segment grew by 13% (19% in local currency), while the U.S. market delivered exceptional growth of 84% (106% in local currency).

A major breakthrough was achieved in the U.S. with the inclusion of Nevisense (EIS) in the NCCN Guidelines for Melanoma, supporting its role in melanoma detection, alongside FDA approval for extended labeling. These milestones further validate the clinical value of the technology and are expected to accelerate adoption.

SciBase also strengthened its strategic position through an expanded collaboration and license agreement with Castle Biosciences, combined with a loan agreement to support continued growth. To further secure its financial foundation, the Board resolved to carry out a rights issue of approximately SEK 83 million and proposed the conversion of outstanding TO2 warrants into shares.

Innovation remains at the core of SciBase’s value proposition. The company announced an expansion of its patent portfolio and presented new clinical evidence, including a study demonstrating that Nevisense can predict atopic dermatitis in newborns. Additional research further positions EIS as a sensitive and valuable tool for assessing skin barrier impairment. This is reflected in the rapid growth of the skin barrier segment, which increased by 294%, highlighting a significant new growth avenue beyond skin cancer detection.

Continued growth in Germany, our core market

  • SciBase is experiencing continued profitable sales growth in Germany, our core European market
  • Currently, Nevisense systems are installed at around 500 private dermatological clinics
  • Over 375,000 tests sold—representing 375,000 patients clinically evaluated for skin cancer—demonstrating a significant impact on early detection
  • In 2025, Sales in Germany within the skin cancer segment increased by 13% (19% in local currency).
  • Renewal of our MDR certification in Europe
  • Our profitability and robust sales growth in Germany demonstrate our market leadership.

Strategic partnership with Castle Biosciences

  • Our new partnership with Castle Biosciences is a testament to our potential
  • Significant unmet needs exist in skin barrier-related conditions like eczema and food allergies, with 20% of infants developing AD.
  • Nevisense Go have been selected for several large studies, paving the way for future growth.
  • SciBase and Castle Biosciences expanded their collaboration and license agreement and entered into a loan agreement
  • The first joint clinical study aims to develop a test that can predict flares in patients with atopic dermatitis (AD), with potential to expand into additional indications
  • Under the agreement, the companies will jointly explore and develop multiple clinical applications within dermatologic diseases

Unlocking US market reimbursement for continued growth

  • SciBase's Nevisense is the sole FDA approved point-of-care device available for melanoma detection in the US.
  • Nevisense included in the NCCN Guidelines for Melanoma
  • Sales in the US skin cancer market increased in 2025 by 84% (106% in local currency)
  • We are actively engaged with private payers and additional Medicare regions to expand accessibility.
  • Our presence in the US market holds immense growth potential.
  • New Publication shows US clinicians' real-world Nevisense experience improves melanoma detection